設(shè)為首頁加入收藏中文版 English

The current position： Home>News

JZB dynamic

Industry information

Media focus

Leader’s attention

Policies and Regulations

Jilin Zhongke Bio-engineering Co., Ltd. (JZB) founded in May 2007. JZB registered address is Changchun City, Jilin Province of P. R. China. Registered capital is 100 million RMB. JZB mainly engaged ... [more]

News

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines
NIH Director Francis S. Collins, M.D., Ph.D., today announced the approval of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.
"I am happy to say that we now have human embryonic stem cell lines eligible for use by our research community under our new stem cell policy," Dr. Collins said. "In accordance with the guidelines, these stem cell lines were derived from embryos that were donated under ethically sound informed consent processes. More lines are under review now, and we anticipate continuing to expand this list of responsibly derived lines eligible for NIH funding."
Children's Hospital Boston developed 11 of the approved lines and Rockefeller University in New York City developed two of the approved lines. An additional 96 lines have been submitted to NIH for either internal administrative review or consideration by the external Working Group for Human Embryonic Stem Cell Eligibility Review and the NIH Advisory Committee to the Director (ACD), including more than 20 that will be considered by the ACD on December 4, 2009. The working group provides findings to the ACD, which makes recommendations to the NIH Director, who decides whether the hESCs may be used in NIH-funded research and lists those deemed eligible on the NIH Human Embryonic Stem Cell Registry.
Research using hESCs is already yielding information about the complex events that occur during human development. Researchers hope that eventually cells differentiated from hESCs may be used to treat a myriad of diseases, conditions, and disabilities and to test the safety of new drugs in the laboratory

上一篇：Geron Enrolls First Patient In Clinical Trial Of GRNOPC1 - Quick Facts

下一篇：A New Milestone: US released the Phase II Stem Cell Clinical Trials

Hepatology Hospital
China-Japan Union Hospital
The Second Hospital
Hospital Jilin Province
The Third Hospital
The First Hospital

版權(quán)所有? 吉林省中科生物工程有限公司吉ICP備12000258號

欧美日韩精品,成人欧美一区二区三区视频不卡 ,高H粗口调教羞辱SM文女王动画,久久国产精品夜色

First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines